A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients.
BACKGROUND
Previous studies have demonstrated an association between genetic polymorphisms of the mu opioid receptor gene (OPRM1) and response to naltrexone treatment. The Asp40 variant genotype previously shown to be associated with naltrexone treatment response is known to be relatively common among Koreans.


OBJECTIVE
This study was conducted to prospectively investigate the relationship between genotype and response to open-label naltrexone treatment in Korean alcohol-dependent subjects.


METHODS
Sixty-three alcohol-dependent subjects were prescribed naltrexone for 12 weeks in combination with cognitive behavioral therapy. Thirty-two subjects were adherent, taking the medication at least 80% of the treatment days [16 Asn40 (A/A) patients and 16 Asp40 variant (A/G or G/G) patients].


RESULTS
Subjects adherent to naltrexone treatment with one or two copies of the Asp40 allele took a significantly longer time than the Asn40 group to relapse (p=0.014). Although not significant, the Asn40 group treated with naltrexone had a 10.6 times greater relapse rate than the Asp40 variant group. There was no significant difference between the Asn40 group and the Asp40 variant group treated with naltrexone in rates of abstinence.


CONCLUSIONS
These results demonstrating a higher therapeutic effect of naltrexone in Korean alcohol-dependent individuals with the Asp40 variant genotype than the Asn40 genotype are consistent with previous study results in individuals of European descent. This is the first study to examine the pharmacogenetics treatment response to naltrexone in non-European subjects.
Kim
Sung-Gon
SG
Department of Psychiatry, School of Medicine, Pusan National University, and Bongseng Memorial Hospital, 1-ga 10, Ami-dong, Seo-gu, Pusan, 602-739, South Korea. sungkim@pusan.ac.kr
Kim
Cheol-Min
CM
Choi
Sam-Wook
SW
Jae
Young-Myo
YM
Lee
Hae-Gook
HG
Son
Bong-Ki
BK
Kim
Jeong-Gee
JG
Choi
Young-Sung
YS
Kim
Han-Oh
HO
Kim
Seong-Yeon
SY
Oslin
David W
DW
D000328:Adult; D000437:Alcoholism / Q000188:drug therapy* / Q000235:genetics / Q000534:rehabilitation; D000483:Alleles; D044466:Asian People / Q000235:genetics; D015928:Cognitive Behavioral Therapy; D005260:Female; D006801:Humans; D007723:Korea; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D017450:Receptors, Opioid, mu / Q000235:genetics*; D012008:Recurrence; D013695:Temperance
D009292:Narcotic Antagonists; D017450:Receptors, Opioid, mu; D009271:Naltrexone
Alcohol Alcohol. 2000 Nov-Dec;35(6):587-93
11093966
J Neurochem. 1992 Jul;59(1):157-63
1613496
Alcohol Alcohol. 1996 Mar;31 Suppl 1:13-6
8736996
Pharmacogenet Genomics. 2006 Sep;16(9):625-36
16906017
Alcohol Clin Exp Res. 2008 Jul;32(7):1113-23
18540916
Mol Psychiatry. 1999 Sep;4(5):476-83
10523821
Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66
17379484
Alcohol. 1989 Jan-Feb;6(1):59-63
2524202
Addiction. 2001 Nov;96(11):1565-73
11784454
Pharmacogenomics J. 2007 Oct;7(5):353-61
17224915
Mol Psychiatry. 1997 Oct-Nov;2(6):490-4
9399694
Biochem Genet. 1993 Aug;31(7-8):321-8
8274138
Am J Psychiatry. 1995 Apr;152(4):613-5
7694913
Alcohol Alcohol. 1996 Mar;31 Suppl 1:33-42
8736999
Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47
11707638
J Clin Psychopharmacol. 2001 Feb;21(1):72-7
11199951
Arch Gen Psychiatry. 2007 Sep;64(9):1069-77
17768272
Pharmacogenomics J. 2004;4(3):184-92
15007373
Arch Gen Psychiatry. 2008 Feb;65(2):135-44
18250251
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13
9689128
Pharmacogenetics. 2002 Jan;12(1):3-9
11773859
J Biol Chem. 2005 Sep 23;280(38):32618-24
16046395
Biol Psychiatry. 2007 Jun 1;61(11):1244-51
17157823
Neuropsychopharmacology. 2000 May;22(5):493-503
10731624
Psychopharmacology (Berl). 2006 Oct;188(3):355-63
16960700
Acta Anaesthesiol Scand. 2004 Nov;48(10):1232-9
15504181
Psychopharmacology (Berl). 1997 Jan;129(1):15-22
9122358
Am J Geriatr Psychiatry. 1997 Fall;5(4):324-32
9363289
Alcohol Clin Exp Res. 2007 Jan;31(1):1-10
17207095
Alcohol Clin Exp Res. 2007 Apr;31(4):555-63
17374034
Exp Clin Psychopharmacol. 2007 Jun;15(3):272-81
17563214
Behav Neurosci. 2006 Dec;120(6):1218-24
17201465
Neuropsychopharmacology. 2003 Aug;28(8):1546-52
12813472
Am J Med Genet B Neuropsychiatr Genet. 2003 Apr 1;118B(1):60-5
12627468
Arch Gen Psychiatry. 1992 Nov;49(11):876-80
1345133
Alcohol Clin Exp Res. 2004 Jul;28(7):986-90
15252283
Neuropharmacology. 1982 Jun;21(6):487-97
6287334
N Engl J Med. 2001 Dec 13;345(24):1734-9
11742047
Alcohol Clin Exp Res. 2004 Dec;28(12):1789-95
15608594
Alcohol Clin Exp Res. 1998 Dec;22(9):2108-10
9884158
Acta Anaesthesiol Scand. 2006 Aug;50(7):787-92
16879459
Arch Gen Psychiatry. 1992 Nov;49(11):881-7
1444726
Am J Addict. 2001 Summer;10(3):258-68
11579624
Neuropsychopharmacology. 2002 Jan;26(1):106-14
11751037